| breast cancer - triple negative | ||||
| mBC - Triple negative (TNBC) - (neo)adjuvant (NA) | mBC - Triple negative (TNBC) - 1st Line (L1) | la/mBC - TNBC - L2 - all population | la/mBC - TNBC - L2 - PDL1 positive | |
| chemotherapy | ||||
| non platinum-based chemotherapy | ||||
| nucleoside analogues (pyrimidine/purine) | ||||
| gemcitabine | IMpassion-132 ... IMpassion-132 ... | IMpassion-132 ... IMpassion-132 ... | ||
| taxanes | ||||
| paclitaxel | ||||
| nab-paclitaxel | FUTURE-SUPER_immunomodulatory subtype | |||
| pegylated liposomal doxorubicin and cyclophosphamide | NSABP B-59/GBG 96-GeparDouze NSABP B-59/GBG 96-GeparDouze | Alice | ||
| platinum-based chemotherapy | ||||
| platinum derivate | ||||
| carboplatin | NSABP B-59/GBG 96-GeparDouze NSABP B-59/GBG 96-GeparDouze | TBCRC IMpassion-132 ... IMpassion-132 ... | IMpassion-132 ... IMpassion-132 ... | |
Study type:
delta: difference in rate or median (if available)
-
About us
-
Contact us
-
Method
-
RSS
Made with
in Lyon
-
Credits
-
Privacy policy
-
